Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

Presentation THT 2025

Regulatory Considerations for the Use of AI for Treating Patients With Heart Failure: The Intersection of Drugs and Devices

Presenter: Alex Cadotte

February 13, 2025

Presentation THT 2024

Regulatory Issues Related to the Introduction of New Percutaneous Pumps

Presenter: Navin K. Kapur

March 06, 2024

Presentation THT 2024

Regulatory Matters Related to Monitoring Devices

Presenter: Liviu Klein

March 06, 2024

Presentation THT 2024

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

Presenter: Maria Rosa Costanzo

March 06, 2024

Presentation THT 2024

Regulatory Aspects of Implementing AI into Heart Failure Diagnostics and Therapeutics

Presenter: Haider Warraich

March 05, 2024

News Features THT 2023

The Promise of AI for Improving Health Equity in Heart Failure

Todd Neale

April 04, 2023

News Conference News THT 2023

Promising Preliminary Results for AccuCinch LV Restoration System in HFrEF

Todd Neale

March 21, 2023

Presentation THT 2023

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

Presenter: Mandeep Mehra

March 20, 2023

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Changfu Wu

March 20, 2023

Presentation THT 2023

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Presenter: Graham Nichol

March 20, 2023

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Mauro Moscucci

March 20, 2023

Presentation THT 2023

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Presenter: Maria Rosa Costanzo

March 20, 2023

Presentation THT 2023

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

Presenter: Ulrich Jorde

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Meir Shinnar

March 20, 2023

Presentation THT 2022

Executing Clinical Follow Up In the Modern Era

Presenter: Jodi Akin

February 02, 2022

Presentation THT 2022

Clinical Trials During COVID-19: Innvestigator Perspective

Presenter: Scott Solomon

February 02, 2022

Presentation THT 2022

Research Consortium / Collabratories

Presenter: Mona Fiuzat

February 02, 2022

Advertisement

Regulatory Considerations for the Use of AI for Treating Patients With Heart Failure: The Intersection of Drugs and Devices

Regulatory Issues Related to the Introduction of New Percutaneous Pumps

Regulatory Matters Related to Monitoring Devices

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

Regulatory Aspects of Implementing AI into Heart Failure Diagnostics and Therapeutics

The Promise of AI for Improving Health Equity in Heart Failure

Promising Preliminary Results for AccuCinch LV Restoration System in HFrEF

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

FDA Introduction

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

FDA Introduction

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

FDA Introduction

Executing Clinical Follow Up In the Modern Era

Clinical Trials During COVID-19: Innvestigator Perspective

Research Consortium / Collabratories

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content